Topic: cardiovascular outcomes
Sanofi and Regeneron are ready to wheel and deal if they win the FDA's blessing to tout their cholesterol drug Praluent's cardiovascular benefits.
The 2018 European Society of Cardiology Congress presented some bombshell data that would shake up the cardiovascular landscape in the coming year.
Analysts are expecting Pfizer to spell out the benefits of its potential blockbuster drug to treat TTR-CM at ESC.
With high hopes for its Vascepa cardiovascular outcomes data due this fall, Amarin has already rolled a pilot TV ad campaign to hone messaging.
Pfizer halts production at a legacy Hospira plant; China works to offer Indian drugmakers streamlined access; Roivant's Sinovant debuts with 11 assets.
More than six years after winning approval, obesity drug Belviq has shown it’s heart-safe, but will that help it sell?
With some new Plavix-matching data, AstraZeneca may have just found a new niche for its blood thinner Brilinta.
Amgen has its sought-after approval to tout its PCSK9 cholesterol med Repatha as a cardiovascular prevention tool.
Sanofi, Regeneron and Amgen, locked in a PCSK9 market battle, are touting the cholesterol drugs' benefits for patients with diabetes.
Anyone looking for a heart-helping class effect from GLP-1 diabetes meds wouldn't be encouraged by the Bydureon data AstraZeneca rolled out Thursday.